View Item 

Show simple item record

Clinical use of amyloid‐positron emission tomography neuroimaging: Practical and bioethical considerations

dc.contributor.authorWitte, Michael M.
dc.contributor.authorFoster, Norman L.
dc.contributor.authorFleisher, Adam S.
dc.contributor.authorWilliams, Monique M.
dc.contributor.authorQuaid, Kimberly
dc.contributor.authorWasserman, Michael
dc.contributor.authorHunt, Gail
dc.contributor.authorRoberts, J. Scott
dc.contributor.authorRabinovici, Gil D.
dc.contributor.authorLevenson, James L.
dc.contributor.authorHake, Ann Marie
dc.contributor.authorHunter, Craig A.
dc.contributor.authorVan Campen, Luann E.
dc.contributor.authorPontecorvo, Michael J.
dc.contributor.authorHochstetler, Helen M.
dc.contributor.authorTabas, Linda B.
dc.contributor.authorTrzepacz, Paula T.
dc.date.accessioned2020-01-13T15:15:32Z
dc.date.available2020-01-13T15:15:32Z
dc.date.issued2015-09
dc.identifier.citationWitte, Michael M.; Foster, Norman L.; Fleisher, Adam S.; Williams, Monique M.; Quaid, Kimberly; Wasserman, Michael; Hunt, Gail; Roberts, J. Scott; Rabinovici, Gil D.; Levenson, James L.; Hake, Ann Marie; Hunter, Craig A.; Van Campen, Luann E.; Pontecorvo, Michael J.; Hochstetler, Helen M.; Tabas, Linda B.; Trzepacz, Paula T. (2015). "Clinical use of amyloid‐positron emission tomography neuroimaging: Practical and bioethical considerations." Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1(3): 358-367.
dc.identifier.issn2352-8729
dc.identifier.issn2352-8729
dc.identifier.urihttps://hdl.handle.net/2027.42/153020
dc.description.abstractUntil recently, estimation of β‐amyloid plaque density as a key element for identifying Alzheimer’s disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid‐positron emission tomography (amyloid‐PET) neuroimaging, this AD hallmark can be detected antemortem. Practitioners and patients need to better understand potential diagnostic benefits and limitations of amyloid‐PET and the complex practical, ethical, and social implications surrounding this new technology. To complement the practical considerations, Eli Lilly and Company sponsored a Bioethics Advisory Board to discuss ethical issues that might arise from clinical use of amyloid‐PET neuroimaging with patients being evaluated for causes of cognitive decline. To best address the multifaceted issues associated with amyloid‐PET neuroimaging, we recommend this technology be used only by experienced imaging and treating physicians in appropriately selected patients and only in the context of a comprehensive clinical evaluation with adequate explanations before and after the scan.
dc.publisherWiley Periodicals, Inc.
dc.publisherAmerican Psychiatric Association
dc.subject.otherBiomarkers
dc.subject.otherAmyloid‐β
dc.subject.otherDiagnostic use
dc.subject.otherPositron emission tomography
dc.subject.otherBioethics in neurology
dc.subject.otherMild cognitive impairment
dc.subject.otherAlzheimer’s disease
dc.subject.otherDementia
dc.titleClinical use of amyloid‐positron emission tomography neuroimaging: Practical and bioethical considerations
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNeurology and Neurosciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/153020/1/dad2jdadm201506006.pdf
dc.identifier.doi10.1016/j.dadm.2015.06.006
dc.identifier.sourceAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
dc.identifier.citedreferenceL. Hinton, C. Franz, J. Friend. Pathways to dementia diagnosis: Evidence for cross‐ethnic differences. Alzheimer Dis Assoc Disord. 18: 2004; 134 – 144
dc.identifier.citedreferenceC.R. Jack, M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, M.C. Carrillo, et al. Introduction to the recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7: 2011; 257 – 262
dc.identifier.citedreferenceG.B. Frisoni, M. Bocchetta, G. Chételat, G.D. Rabinovici, M.J. de Leon, J. Kaye, et al. Imaging markers for Alzheimer disease: Which vs how. Neurology. 81: 2013; 487 – 500
dc.identifier.citedreferenceB. Dubois, H.H. Feldman, C. Jacova, H. Hampel, J.L. Molinuevo, K. Blennow, et al. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG‐2 criteria. Lancet Neurol. 13: 2014; 614 – 629
dc.identifier.citedreferenceE. Hogervorst, L. Barnetson, K.A. Jobst, Z. Nagy, M. Combrinck, A.D. Smith. Diagnosing dementia: Interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer’s disease. Dement Geriatr Cogn Disord. 11: 2000; 107 – 113
dc.identifier.citedreferenceH. Johnson, W.P. Bouman, G. Pinner. On telling the truth in Alzheimer’s disease: A pilot study of current practice and attitudes. Int Psychogeriatr. 12: 2000; 221 – 229
dc.identifier.citedreferenceB.D. Carpenter, C. Xiong, E.K. Porensky, M.M. Lee, P.J. Brown, M. Coats, et al. Reaction to a dementia diagnosis in individuals with Alzheimer’s disease and mild cognitive impairment. J Am Geriatr Soc. 56: 2008; 405 – 412
dc.identifier.citedreferenceJ. Lecouturier, C. Bamford, J.C. Hughes, J.J. Francis, R. Foy, M. Johnston, et al. Appropriate disclosure of a diagnosis of dementia: Identifying the key behaviours of “best practice”. BMC Health Serv Res. 8: 2008; 95
dc.identifier.citedreferenceA. Bradford, M.E. Kunik, P. Schulz, S.P. Williams, H. Singh. Missed and delayed diagnosis of dementia in primary care prevalence and contributing factors. Alzheimer Dis Assoc Disord. 23: 2009; 306 – 314
dc.identifier.citedreferenceG.T. Grossberg, D.D. Christensen, P.A. Griffith, D.R. Kerwin, G. Hunt, E.J. Hall. The art of sharing the diagnosis and management of Alzheimer’s disease with patients and caregivers: Recommendations of an expert consensus panel. Prim Care Companion J Clin Psychiatry. 12: 2010, PCC.09cs00833
dc.identifier.citedreferenceJ.A. Schneider, D.A. Bennett. Where vascular meets neurodegenerative disease. Stroke. 41 (10 Suppl): 2010; S144 – S146
dc.identifier.citedreferenceV.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, O. Salvado, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol. 12: 2013; 357 – 367
dc.identifier.citedreferenceM.A. Mintun, G.N. Larossa, Y.I. Sheline, C.S. Dence, S.Y. Lee, R.H. Mach, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 67: 2006; 446 – 452
dc.identifier.citedreferenceE.C. Mormino, J.T. Kluth, C.M. Madison, G.D. Rabinovici, S.L. Baker, B.L. Miller, et al. Episodic memory loss is related to hippocampal‐mediated beta‐amyloid deposition in elderly subjects. Brain. 132 (Pt 5): 2009; 1310 – 1323
dc.identifier.citedreferenceK.E. Pike, G. Savage, V.L. Villemagne, S. Ng, S.A. Moss, P. Maruff, et al. Beta‐amyloid imaging and memory in non‐demented individuals: Evidence for preclinical Alzheimer’s disease. Brain. 130 (Pt11): 2007; 2837 – 2844
dc.identifier.citedreferenceV.L. Villemagne, K.E. Pike, G. Chetelat, K.A. Ellis, R.S. Mulligan, P. Bourgeat, et al. Longitudinal assessment of beta‐amyloid and cognition in aging and Alzheimer disease. Ann Neurol. 69: 2011; 181 – 192
dc.identifier.citedreferenceHighlights of prescribing information: Amyvid (florbetapir F 18 injection) for intravenous use. 2014, Available at: http://pi.lilly.com/us/amyvid‐uspi.pdf. Accessed June 4, 2014
dc.identifier.citedreferenceVizamyl (flutemetamol F 18 injection): Highlights of prescribing information. 2013, Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203137s002lbl.pdf. Accessed June 4, 2014
dc.identifier.citedreferenceHighlights of prescribing information. Neuraceq (florbetaben F 18 injection), for intravenous use. 2013, Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf. Accessed June 4, 2014
dc.identifier.citedreferenceE.P. Klein, J. Kaye. Dementia specialists and early adoption. J Alzheimers Dis. 33: 2013; 445 – 450
dc.identifier.citedreferenceA.M. Fagan. CSF biomarkers of Alzheimer’s disease: Impact on disease concept, diagnosis, and clinical trial design. Adv Geriatr. 2014: 2014; 14, Article ID 302712
dc.identifier.citedreferenceB.R. Matthews, B.L. Miller. Alzheimer’s disease The behavioral neurology of dementia. 2009; Cambridge University Press: New York; 56 – 73
dc.identifier.citedreferenceP.M. Doraiswamy, R.A. Sperling, K. Johnson, E.M. Reiman, T.Z. Wong, M.N. Sabbagh, et al. AV45‐A11 Study Group. Florbetapir F 18 amyloid PET and 36‐month cognitive decline: A prospective multicenter study. Mol Psychiatry. 19: 2014; 1044 – 1051
dc.identifier.citedreferenceS.M. Landau, M.A. Mintun, A.D. Joshi, R.A. Koeppe, R.C. Petersen, P.S. Aisen, et al. Alzheimer’s Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 72: 2012; 578 – 586
dc.identifier.citedreferenceC.H. Kawas, D.E. Greenia, S.S. Bullain, C.M. Clark, M.J. Pontecorvo, A.D. Joshi, et al. Amyloid imaging and cognitive decline in nondemented oldest‐old: The 90+ study. Alzheimers Dement. 9: 2013; 199 – 203
dc.identifier.citedreferenceM. Grundman, M. Pontecorvo, S.P. Salloway, P.M. Doraiswamy, A.S. Fleisher, C.H. Sadowsky, et al. AV45‐A17 Study Group. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 27: 2013; 4 – 15
dc.identifier.citedreferenceR. Ossenkoeple, N.D. Prins, Y.A. Pijnenburg, A.W. Lemstra, W.M. van der Flier, S.F. Adriaanse, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 9: 2013; 414 – 421
dc.identifier.citedreferenceC.M. Connell, J.S. Roberts, S.J. McLaughlin, B.D. Carpenter. Black and white adult family members’ attitudes toward a dementia diagnosis. J Am Geriatr Soc. 57: 2009; 1562 – 1568
dc.identifier.citedreferenceM.M. Witte, J. Barnes, J. Lingler, M. Agronin, H. Hochstetler, K. Healey, et al. Testing the use of standardized scripts for disclosing “hypothetical/mock” amyloid PET scan results to nondemented cognitively‐impaired patients and their care partners. Alzheimers Dement. 9 (Suppl): 2013; P131 – P132
dc.identifier.citedreferenceO. Karnieli‐Miller, P. Werner, J. Aharon‐Peretz, G. Sinoff, S. Eidelman. Expectations, experiences, and tensions in the memory clinic: The process of diagnosis disclosure of dementia within a triad. Int Psychogeriatr. 24: 2012; 1756 – 1770
dc.identifier.citedreferenceNuffield Council on Bioethics. Dementia: Ethical issues. 2009, Available at: http://nuffieldbioethics.org/project/dementia/. Accessed June 4, 2014
dc.identifier.citedreferenceM.A. Fischer, M.R. Stedman, J. Lii, C. Vogeli, W.H. Shrank, M.A. Brookhart, et al. Primary medication non‐adherence: Analysis of 195,930 electronic prescriptions. J Gen Intern Med. 25: 2010; 284 – 290
dc.identifier.citedreferenceM.A. Nowrangi, V. Rao, C.G. Lyketsos. Epidemiology, assessment, and treatment of dementia. Psychiatr Clin North Am. 34: 2011; 275 – 294
dc.identifier.citedreferenceA. Leuzy, S. Gauthier. Ethical issues in Alzheimer’s disease: An overview. Expert Rev Neurother. 12: 2012; 557 – 567
dc.identifier.citedreferenceM. Storandt, J.C. Morris. Ascertainment bias in the clinical diagnosis of Alzheimer disease. Arch Neurol. 67: 2010; 1364 – 1369
dc.identifier.citedreferenceY. Stern. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 11: 2012; 1006 – 1012
dc.identifier.citedreferenceL.J. Trevena, B.J. Zikmund‐Fisher, A. Edwards, W. Gaissmaier, M. Galesic, P.K. Han, et al. Presenting quantitative information about decision outcomes: A risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak. 13 (Suppl 2): 2013; S7
dc.identifier.citedreferenceS.M. Lee, K. Roen, A. Thornton. The psychological impact of a diagnosis of Alzheimer’s disease. Dementia (London). 13: 2014; 289 – 305
dc.identifier.citedreferenceJ.S. Roberts, K.D. Christensen, R.C. Green. Using Alzheimer’s disease as a model for genetic risk disclosure: Implications for personal genomics. Clinical Genetics. 80: 2011; 407 – 414
dc.identifier.citedreferenceJ.S. Roberts, L. Dunn, G. Rabinovici. Amyloid imaging, risk disclosure, and Alzheimer’s disease: Ethical and practical issues. Neurodegener Dis Manag. 3: 2013; 219 – 229
dc.identifier.citedreferenceE.M. Mitsis, H.A. Bender, L. Kostakoglu, J. Machac, J. Martin, J.L. Woehr, et al. A consecutive case series experience with [18F] florbetapir PET imaging in an urban dementia center: Impact on quality of life, decision making, and disposition. Mol Neurodegener. 9: 2014; 10
dc.identifier.citedreferenceR. Vandenberghe, K. Van Laere, A. Ivanoiu, E. Salmon, C. Bastin, E. Triau, et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol. 68: 2010; 319 – 329
dc.identifier.citedreferenceC.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, M.A. Mintun, et al. Use of florbetapir‐PET for imaging beta‐amyloid pathology. JAMA. 305: 2011; 275 – 283
dc.identifier.citedreferenceH. Barthel, H.J. Gertz, S. Dresel, O. Peters, P. Bartenstein, K. Buerger, et al. Cerebral amyloid‐β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol. 10: 2011; 424 – 435
dc.identifier.citedreferenceW.E. Klunk. Amyloid imaging as a biomarker for cerebral beta‐amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 32 (Suppl 1): 2011; S20 – S36
dc.identifier.citedreferenceK.A. Johnson, S. Minoshima, N.I. Bohnen, K.J. Donohoe, N.L. Foster, P. Herscovitch, et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 54: 2013; 476 – 490
dc.identifier.citedreferenceK.A. Johnson, S. Minoshima, N.I. Bohnen, K.J. Donohoe, N.L. Foster, P. Herscovitch, et al. Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society of Nuclear Medicine and Molecular Imaging. Alzheimers Dement. 9: 2013; e106 – e109
dc.identifier.citedreferenceF.B. Waldorff, D.V. Buss, A. Eckermann, M.L. Rasmussen, N. Keiding, S. Rishøj, et al. Efficacy of psychosocial intervention in patients with mild Alzheimer’s disease: The multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). BMJ. 345: 2012; e4693
dc.identifier.citedreferenceW. Thies, L. Bleiler Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement. 9: 2013; 208 – 245
dc.identifier.citedreferenceWorld Health Organization. Classifications: International classification of diseases, 10th revision. 2014, Available at: http://www.who.int/classifications/icd/en/index.html. Accessed June 4, 2014
dc.identifier.citedreferenceAmerican Psychiatric Association Diagnostic and statistical manual of mental disorders, Fifth Edition, Text Revision. 2000; American Psychiatric Association: Washington, DC
dc.identifier.citedreferenceG.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., C.H. Kawas, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7: 2011; 263 – 269
dc.identifier.citedreferenceT.G. Beach, S.E. Monsell, L.E. Phillips, W. Kukull. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005‐2010. J Neuropathol Exp Neurol. 71: 2012; 266 – 273
dc.identifier.citedreferenceT.G. Beach, L.I. Sue, D.G. Walker, M.N. Sabbagh, G. Serrano, B.N. Dugger, et al. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer’s disease: Implications for amyloid imaging. J Alzheimers Dis. 28: 2012; 869 – 876
dc.identifier.citedreferenceS. Haneuse, E. Larson, R. Walker, T. Montine, J. Sonnen. Neuropathology‐based risk scoring for dementia diagnosis in the elderly. J Alzheimers Dis. 17: 2009; 875 – 885
dc.identifier.citedreferenceD.S. Knopman, S.T. DeKosky, J.L. Cummings, H. Chui, J. Corey‐Bloom, N. Relkin, et al. Practice parameter: Diagnosis of dementia (an evidence‐based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56: 2001; 1143 – 1153
dc.identifier.citedreferenceB.E. Gay, K.I. Taylor, U. Hohl, M. Tolnay, H.B. Staehelin. The validity of clinical diagnoses of dementia in a group of consecutively autopsied memory clinic patients. J Nutr Health Aging. 12: 2008; 132 – 137
dc.identifier.citedreferenceK.L. Newell, B.T. Hyman, J.H. Growdon, E.T. Hedley‐Whyte. Application of the National Institute on Aging (NIA)‐Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol. 58: 1999; 1147 – 1155
dc.identifier.citedreferenceM.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7: 2011; 270 – 279
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
dad2jdadm201506006.pdf
Size:
426.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.